Overview

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.

Phase:

Phase 3

Details

Lead Sponsor:

ACADIA Pharmaceuticals Inc.

Treatments:

Pimavanserin